Aminosteroid NMBA

Aminosteroid NMBAs are a class of synthetic, non-depolarizing neuromuscular blocking agents derived from a steroid backbone with one or more quaternary ammonium groups[8]. They act as competitive antagonists at nicotinic acetylcholine receptors (nAChRs) on the motor endplate of skeletal muscle, preventing acetylcholine-induced depolarization and thus inhibiting muscle contraction[4][5][7][8]. Common agents in this group include rocuronium, vecuronium, and pancuronium. These drugs are used most often to facilitate intubation and mechanical ventilation, as well as to maintain muscle relaxation during general anesthesia. Their duration and metabolism depend on the specific molecule and the patient’s renal and hepatic function. Unlike benzylisoquinolinium NMBAs, aminosteroids rarely cause histamine release. Their effects are reversible by agents such as sugammadex (for some drugs) or acetylcholinesterase inhibitors, and experimental agents like calabadion are in development for broader reversal[1][2][4][8]. Summary: "Aminosteroid NMBA" is a drug class term, not a single target. These drugs act as competitive antagonists at the nicotinic acetylcholine receptor (their primary molecular target), and the most accurate structured data should be linked to each individual drug or, even more specifically, to the nicotinic acetylcholine receptor (muscle type). If your intent was the receptor, use "Nicotinic acetylcholine receptor (muscle type)". For the class, structured data will be incomplete or inapplicable for many target-specific fields.

Other names

Aminosteroidal neuromuscular blocking agentaminosteroid NMBAaminosteroidal NMBAaminosteroid muscle relaxant

Competitive antagonism of the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction, preventing acetylcholine from binding and inhibiting depolarization and muscle contraction[4][7][8]